AZ Delta

Running trials

• Not yet recruiting

  Evaluating the Safety and Performance of the Eight Medical Hyperthermia System IV 1.0 for HIVEC in NMIBC.

  NCT07758881· Eight Medical International BV· Source

• Recruiting

  Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  NCT07648264· Phase 3· CSL Behring· Source

• Recruiting

  A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

  NCT07811193· Phase 2· Vividion Therapeutics, Inc.· Source

• Not yet recruiting

  A Study of Barrett's Esophagus Patients: Optimization of a Risk Model to Better Predict the Development of Cancer Recurrence and the Effect of Risk Profile Disclosure on Patient Quality of Life and Fear of Cancer

  NCT07455422· University Hospital, Antwerp· Source

• Recruiting

  Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  NCT07441694· Phase 1· Incyte Corporation· Source

• Active, not recruiting

  Hydrogel Assessment for Local Treatment of Osteoarthritis

  NCT07516457· Allegro NV/SA· Source

• Recruiting

  A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

  NCT07218341· Phase 4· Eli Lilly and Company· Source

• Recruiting

  A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in Belgium

  NCT07382440· AbbVie· Source

• Recruiting

  Effect of IMT in Patients After Acute Exacerbations of COPD

  NCT07213128· KU Leuven· Source

• Recruiting

  Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

  NCT06962137· Phase 2· Universitaire Ziekenhuizen KU Leuven· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Optimized Expansion of the Implanted Transcatheter Aortic Valve

  NCT07042529· Ole De Backer· Source

• Recruiting

  CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Phase 3· Novo Nordisk A/S· Source

• Active, not recruiting

  A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

  NCT07005128· Phase 3· Amgen· Source

• Recruiting

  A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer

  NCT06523374· University Hospital, Antwerp· Source

• Recruiting

  A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

  NCT07005102· Phase 2/3· AbbVie· Source

• Recruiting

  Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  NCT07037459· Phase 3· Amgen· Source

• Recruiting

  A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine

  NCT06682988· Phase 2· AbbVie· Source

• Recruiting

  Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target Volume

  NCT06719440· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Source

• Recruiting

  Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

  NCT06801834· Phase 3· Gilead Sciences· Source

• Recruiting

  Improving the Use of Immunotherapy to Treat Liver Cancer

  NCT07623265· Universitaire Ziekenhuizen KU Leuven· Source

• Active, not recruiting

  A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

  NCT06686615· Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company· Source

• Recruiting

  Study on the Clinical Efficacy of Teclistamab and Talquetamab

  NCT06477783· Universitaire Ziekenhuizen KU Leuven· Source

• Recruiting

  Perioperative SDD to Prevent Infectious Complications After Esophagectomy

  NCT05865743· Phase 3· Radboud University Medical Center· Source

• Active, not recruiting

  A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

  NCT06388564· Phase 2· Incyte Corporation· Source

• Recruiting

  Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium

  NCT06581042· AbbVie· Source

• Active, not recruiting

  A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  NCT06508658· Phase 3· Genmab· Source

• Recruiting

  Stereotactic Body Radiation Therapy for Inoperable Non-metastasized Pancreatic Adenocarcinoma

  NCT06691425· Cancer Research Antwerp· Source

• Recruiting

  Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

  NCT06252649· Phase 3· Amgen· Source

• Recruiting

  The RECLAIM Study.

  NCT06450444· Salvia BioElectronics· Source

• Recruiting

  Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  NCT05485961· Phase 2/3· CSL Behring· Source

• Recruiting

  Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention

  NCT06095765· Phase 3· AZ Sint-Jan AV· Source

• Recruiting

  A Phase 1/2 study of Enzomenib (DSP-5336) in Patients with Acute leukemia

  2022-502741-10-00· Phase 1/2· Sumitomo Pharma America Inc.· Source

• Recruiting

  Physical Activity Coaching After Surgery for Patients With Resectable Non-small Cell Lung Cancer

  NCT06057766· University Hospital, Ghent· Source

• Recruiting

  A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

  NCT06149286· Phase 3· Regeneron Pharmaceuticals· Source

• Active, not recruiting

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· Phase 3· Taiho Oncology, Inc.· Source

• Recruiting

  Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (THUNDER): A Two-part Phase 2/3 Trial

  2022-501551-90-00· Phase 2/3· Ziekenhuis Aan De Stroom· Source

• Recruiting

  Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

  NCT06282588· Phase 2/3· Cancer Research Antwerp· Source

• Recruiting

  A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

  NCT05730036· Phase 3· Regeneron Pharmaceuticals· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  Afimkibart (RO7790121) for the Treatment of Moderate to Severe Active Crohn's Disease

  NCT05910528· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Zigakibart in Adults With IgA Nephropathy

  NCT05852938· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Atacicept in Subjects With IgA Nephropathy

  NCT04716231· Phase 3· Vera Therapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

  NCT06896890· Phase 1/2· Inhatarget Therapeutics· Source

• Recruiting

  An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

  NCT05907057· Phase 3· Servier Affaires Médicales· Source

• Active, not recruiting

  First Evaluation of a Craniofacial Nerve Stimulation System in Chronic Migraine

  NCT05858801· Salvia BioElectronics· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Liquid Biopsies in Esophageal Cancer

  NCT05704530· Universitaire Ziekenhuizen KU Leuven· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· AbbVie· Source

Showing 50 of 88.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease5 recruiting
• Gastric and oesophageal cancer5 recruiting
• Lung cancer5 recruiting
• Childhood cancers4 recruiting
• Barrett's oesophagus3 recruiting
• Multiple myeloma3 recruiting
• Prostate cancer3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Atrial fibrillation2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Colorectal cancer2 recruiting
• COPD2 recruiting
• Crohn's disease2 recruiting
• Essential tremor2 recruiting
• Heart failure2 recruiting
• Myelodysplastic syndromes2 recruiting
• Obesity2 recruiting
• Parkinson disease2 recruiting
• Amyloidosis1 recruiting
• Aortic stenosis1 recruiting
• Bladder cancer1 recruiting
• Chronic kidney disease1 recruiting
• Dystonia1 recruiting
• Glioblastoma1 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Migraine1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

  NCT06595563· Phase 2· Jules Bordet Institute· Source

• Withdrawn

  Knee OsteoArthritis Long-term Assessment

  NCT06839222· Allegro NV/SA· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  Quality-of-Life Index (Q-Index)

  NCT06209502· Koios Care· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease

  2022-502828-42-00· Phase 2· Genentech Inc.· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients

  2022-501183-17-00· Phase 1/2· Inhatarget Therapeutics· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Abivax S.A.· Source

• Completed

  ChAracterizing the Remission Status in Patients With Ulcerative Colitis Treated by 5-ASA

  NCT05992142· Phase 4· Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW· Source

• Terminated

  A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

  NCT05556616· Phase 1· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolism in people with irregular and often rapid heartbeat (atrial fibrillation), and at risk for stroke

  NCT05643573· Phase 3· Bayer AG· Source

• Active, not recruiting

  Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma

  NCT05471843· Phase 1/2· BeOne Medicines· Source

• Completed

  A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)

  NCT04959851· Takeda· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Terminated

  A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)

  NCT04809467· Phase 1/2· Incyte Corporation· Source

• Completed

  A Study of Surgical Interventions in Fistulizing Conditions

  NCT04940611· Takeda· Source

• Active, not recruiting

  Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).

  NCT04895722· Phase 2· Merck Sharp & Dohme LLC· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Incyte Corporation· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Incyte Corporation· Source

• Completed

  A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer’s Disease

  2022-501188-42-00· Phase 2· Janssen - Cilag International· Source

• Completed

  Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis

  NCT04607837· Phase 2· Pfizer· Source

• Terminated

  Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

  NCT04093362· Phase 3· Taiho Oncology, Inc.· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)

  NCT04437303· Phase 4· St. Antonius Hospital· Source

• Terminated

  Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis

  NCT04883840· Phase 2/3· Universitaire Ziekenhuizen KU Leuven· Source

• Completed

  Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

  NCT04472598· Phase 3· AbbVie· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Hutchison Medipharma Limited· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  COronary and MICrocirculatory Measurements in Patients With Aortic Valve Stenosis.

  NCT04420325· Universitaire Ziekenhuizen KU Leuven· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04256421· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

  NCT03914326· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice

  NCT03782207· Hoffmann-La Roche· Source

• Completed

  Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

  NCT03593590· Hoffmann-La Roche· Source

• Active, not recruiting

  The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL

  NCT03463057· Phase 2· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source

• Active, not recruiting

  Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)

  NCT03425643· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source

• Completed

  Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke

  NCT02898610· Phase 3· University College Dublin· Source

• Completed

  A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease

  NCT02620046· Phase 3· Takeda· Source

• Completed

  Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation

  NCT01938248· Phase 4· Population Health Research Institute· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Barrett's oesophagus3 works · 3 trials